Jim Simons Oncorus, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.28 - $0.45 $40,022 - $64,321	-142,936 Reduced 49.81%	144,000 $50,000
Q4 2022 Feb 13, 2023	BUY	$0.24 - $0.76 $18,576 - $58,826	77,403 Added 36.94%	286,936 $73,000
Q3 2022 Nov 14, 2022	SELL	$0.85 - $1.65 $6,729 - $13,063	-7,917 Reduced 3.64%	209,533 $178,000
Q2 2022 Aug 12, 2022	BUY	$1.04 - $1.86 $43,594 - $77,967	41,918 Added 23.88%	217,450 $274,000
Q1 2022 May 13, 2022	BUY	$1.44 - $5.62 $232,462 - $907,247	161,432 Added 1144.91%	175,532 $312,000
Q4 2021 Feb 11, 2022	SELL	$5.03 - $11.63 $80,334 - $185,742	-15,971 Reduced 53.11%	14,100 $74,000
Q3 2021 Nov 12, 2021	BUY	$9.29 - $14.27 $279,359 - $429,113	30,071 New	30,071 $281,000

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.